BioSpecifics Technologies Corp. (NASDAQ: BSTC) is a biopharmaceutical company that is focused on developing an injectable collagenase for various clinical indications. Under the XIAFLEX name, BioSpecifics provides injectable collagenase for the treatment of adult Dupuytren’s contracture patients with a palpable cord and for Peyronie’s disease, frozen shoulder, cellulite, human lipoma and canine lipoma indications as well as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs. For more information, visit the company’s website at www.biospecifics.com.